MX375790B - Capsula resistente al abuso. - Google Patents

Capsula resistente al abuso.

Info

Publication number
MX375790B
MX375790B MX2015012742A MX2015012742A MX375790B MX 375790 B MX375790 B MX 375790B MX 2015012742 A MX2015012742 A MX 2015012742A MX 2015012742 A MX2015012742 A MX 2015012742A MX 375790 B MX375790 B MX 375790B
Authority
MX
Mexico
Prior art keywords
abuse
capsule
active pharmaceutical
abuse resistant
susceptible active
Prior art date
Application number
MX2015012742A
Other languages
English (en)
Other versions
MX2015012742A (es
Inventor
Simone Wengner
Original Assignee
Scherer Technologies Llc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX375790(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scherer Technologies Llc R P filed Critical Scherer Technologies Llc R P
Publication of MX2015012742A publication Critical patent/MX2015012742A/es
Publication of MX375790B publication Critical patent/MX375790B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a una cápsula o relleno de cápsula de liberación inmediata y liberación extendida que mitiga el abuso de ingredientes farmacéuticos activos susceptibles al abuso por medio de inyección intravenosa; el relleno comprende una formulación parenteral líquida resistente al abuso que cuando se mezcla con agua y se calienta resulta en una mezcla turbia, viscosa y burbujeante que no es inyectable con una jeringa estándar de insulina; el ingrediente farmacéutico activo susceptible al abuso se selecciona del grupo que consiste en opiáceos, opioides, tranquilizantes, estimulantes y narcóticos.
MX2015012742A 2013-03-15 2014-03-14 Capsula resistente al abuso. MX375790B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794714P 2013-03-15 2013-03-15
US14/204,259 US10420729B2 (en) 2013-03-15 2014-03-11 Abuse resistant capsule
PCT/EP2014/055045 WO2014140231A1 (en) 2013-03-15 2014-03-14 Abuse resistant capsule

Publications (2)

Publication Number Publication Date
MX2015012742A MX2015012742A (es) 2016-06-21
MX375790B true MX375790B (es) 2025-03-07

Family

ID=51528060

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020009411A MX388311B (es) 2013-03-15 2014-03-14 Capsula resistente al abuso
MX2015012742A MX375790B (es) 2013-03-15 2014-03-14 Capsula resistente al abuso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020009411A MX388311B (es) 2013-03-15 2014-03-14 Capsula resistente al abuso

Country Status (15)

Country Link
US (4) US10420729B2 (es)
EP (3) EP3446681B1 (es)
JP (4) JP6395734B2 (es)
CN (2) CN105358132B (es)
AR (1) AR095343A1 (es)
AU (3) AU2014230481B2 (es)
CA (1) CA2902501C (es)
CY (1) CY1120959T1 (es)
DK (1) DK2968129T3 (es)
ES (1) ES2700517T3 (es)
HU (1) HUE040530T2 (es)
MX (2) MX388311B (es)
PT (1) PT2968129T (es)
SI (1) SI2968129T1 (es)
WO (1) WO2014140231A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
CA2569958C (en) 2004-06-12 2016-03-22 Jane C. Hirsh Abuse-deterrent drug formulations
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
PL2456424T3 (pl) 2009-07-22 2013-12-31 Gruenenthal Gmbh Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
PE20131102A1 (es) 2010-09-02 2013-10-12 Gruenenthal Chemie Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
NO2736497T3 (es) 2011-07-29 2018-01-20
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10420729B2 (en) 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015103379A1 (en) * 2013-12-31 2015-07-09 Kashiv Pharma, Llc Abuse-resistant drug formulations
CN106572980A (zh) * 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
KR20180004756A (ko) 2015-05-06 2018-01-12 신애질 코포레이션 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
US10662146B2 (en) 2015-09-15 2020-05-26 Praxis Bioresearch, LLC Prodrugs of fencamfamine
US20170312226A1 (en) * 2016-04-28 2017-11-02 Ascent Pharmaceuticals, Inc. Pharmaceutical dosage forms
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
EP3522890A4 (en) * 2016-10-10 2020-06-03 Rhodes Pharmaceuticals L.P. PHARMACEUTICAL RESINATE COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US9931303B1 (en) 2017-02-06 2018-04-03 Alcobra Ltd. Abuse deterrent formulations of amphetamine
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
US20210378970A1 (en) * 2018-02-26 2021-12-09 R.P. Scherer Technologies, Llc Pharmaceutical dosage form for an emulsion of simethicone and loperamide
GB201809976D0 (en) * 2018-06-18 2018-08-01 Neurocentrx Pharma Ltd Novel formulations
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
CN110483669A (zh) * 2019-08-13 2019-11-22 天津大学 一种基于二烯丙基丙二酰脲的聚合物及其制备方法
AU2021238345A1 (en) * 2020-03-18 2022-10-06 R.P. Scherer Technologies, Llc Softgel capsules
CA3213461A1 (en) * 2021-04-01 2022-10-06 Giang Hoang Thuy Au Phospholipids as anion chelating agents in pharmaceutical formulations
MX2024003466A (es) * 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.
WO2024220471A1 (en) * 2023-04-17 2024-10-24 Monroe Mary Beth Surfactants for polyurethane foam synthesis
WO2024243856A1 (en) * 2023-05-31 2024-12-05 Phytohealth Corporation An oral soft capsule that encapsulates a nalbuphine formulation
WO2024254056A1 (en) * 2023-06-08 2024-12-12 Catalent Ontario Limited Modified release fill compositions for dosage forms and methods of preparation and use thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US6340471B1 (en) 1999-12-30 2002-01-22 Alvin Kershman Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6541025B1 (en) 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
WO2003013476A1 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2004004693A1 (en) 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20050191244A1 (en) * 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
ATE454169T1 (de) 2003-03-13 2010-01-15 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050271594A1 (en) 2004-06-04 2005-12-08 Groenewoud Pieter J Abuse resistent pharmaceutical composition
ITMI20041317A1 (it) 2004-06-30 2004-09-30 Ibsa Inst Biochimique Sa Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento
GB0506982D0 (en) 2005-04-06 2005-05-11 Mw Encap Ltd Abuse resistant capsules
US8252326B2 (en) 2005-06-01 2012-08-28 Catalent Australia Pty Ltd. Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10
CA2627292C (en) * 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
JP5406529B2 (ja) * 2005-10-26 2014-02-05 バナー ファーマキャプス， インコーポレイテッド カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム
WO2008134071A1 (en) 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
US20090082466A1 (en) 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
US9265724B2 (en) 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US20080027011A1 (en) * 2005-12-20 2008-01-31 Hassan Nached Homogeneous paste and gel formulations
CA2645855C (en) 2006-03-16 2015-02-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20070281065A1 (en) 2006-06-06 2007-12-06 Modliszewski James J Kappa-2 carrageenan composition and products made therefrom
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
WO2008150526A1 (en) 2007-06-04 2008-12-11 Shear/Kershman Laboratories, Inc. Tamper resistant lipid-based oral dosage form for opioid agonists
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US20110097395A1 (en) 2008-03-08 2011-04-28 Najib Babul Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
US8420700B1 (en) 2008-06-04 2013-04-16 James M. Bausch Tamper resistant lipid-based oral dosage form for sympathomimetic amines
WO2010044842A1 (en) 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Tamper resistant oral dosage forms containing an embolizing agent
FR2939542B1 (fr) 2008-12-04 2012-08-03 Advanced Track & Trace Procede et dispositif de protection d'un recipient et etiquette pour leur mise en oeuvre
US8460640B2 (en) 2008-12-12 2013-06-11 Paladin Labs, Inc. Narcotic drug formulations with decreased abuse potential
EP2448406B1 (en) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
WO2010100414A1 (en) 2009-03-04 2010-09-10 Orexo Ab Abuse resistant formulation
CA2755808C (en) 2009-03-18 2016-01-19 Evonik Roehm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
US9125867B2 (en) * 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
WO2012007159A2 (en) * 2010-07-14 2012-01-19 Grünenthal GmbH Novel gastro-retentive dosage forms
US20120171277A1 (en) 2011-01-03 2012-07-05 Royds Robert B Abuse resistant transdermal drug delivery patch including a release-enhanced antagonist
EP2726065A4 (en) 2011-06-30 2014-11-26 Neos Therapeutics Lp MISS-BROKEN MEDICINAL PRODUCTS
US10420729B2 (en) 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule

Also Published As

Publication number Publication date
EP3824878A1 (en) 2021-05-26
EP3446681A1 (en) 2019-02-27
WO2014140231A1 (en) 2014-09-18
AU2014230481A1 (en) 2015-09-10
AU2018214110B2 (en) 2019-08-22
JP2021073196A (ja) 2021-05-13
JP2019011332A (ja) 2019-01-24
CA2902501A1 (en) 2014-09-18
JP2023051939A (ja) 2023-04-11
CN110585165B (zh) 2022-08-12
PT2968129T (pt) 2018-12-04
AU2019264648B2 (en) 2021-02-25
US12133922B2 (en) 2024-11-05
SI2968129T1 (sl) 2019-01-31
CN105358132A (zh) 2016-02-24
DK2968129T3 (en) 2018-12-17
CA2902501C (en) 2022-05-24
JP7646354B2 (ja) 2025-03-17
CN110585165A (zh) 2019-12-20
US20220362160A1 (en) 2022-11-17
US10420729B2 (en) 2019-09-24
ES2700517T3 (es) 2019-02-18
US20140271835A1 (en) 2014-09-18
US10744097B2 (en) 2020-08-18
US20200009064A1 (en) 2020-01-09
EP2968129A1 (en) 2016-01-20
AR095343A1 (es) 2015-10-07
EP2968129B1 (en) 2018-09-05
AU2018214110A1 (en) 2018-08-30
EP3446681B1 (en) 2020-12-23
AU2014230481B2 (en) 2018-05-10
CY1120959T1 (el) 2019-12-11
US11464747B2 (en) 2022-10-11
HUE040530T2 (hu) 2019-03-28
MX2015012742A (es) 2016-06-21
CN105358132B (zh) 2019-10-15
EP3824878B1 (en) 2025-11-12
US20160374948A1 (en) 2016-12-29
JP6820117B2 (ja) 2021-01-27
MX2020009411A (es) 2021-11-30
MX388311B (es) 2025-03-19
AU2019264648A1 (en) 2019-12-05
JP2016510792A (ja) 2016-04-11
JP6395734B2 (ja) 2018-09-26
BR112015022583A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
MX375790B (es) Capsula resistente al abuso.
ZA202102906B (en) Liquid protein formulations containing viscosity-lowering agents
MX2018006171A (es) Jeringa de plastico precargada que contiene un antagonista de vegf.
AR088375A1 (es) Auto-inyector
EA201790074A1 (ru) Автоматическое устройство для введения лекарственного препарата с визуальной индикацией хода процесса введения
MX383779B (es) Dispositivo de inyección de múltiples cámaras.
EA201791333A1 (ru) Производные глюкагона с улучшенной стабильностью
WO2015034870A3 (en) Double-chamber mixing syringe and method of use
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
MX2022004859A (es) Una forma de dosificacion parenteral estable de acetato de cetrorelix.
EA201591664A1 (ru) Инъекторное устройство многократного использования для шприца
MX2016014738A (es) Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
EA201591666A1 (ru) Инъекторное устройство многократного использования для шприца
ECSP15000500A (es) Solucion de acetaminofen supersaturada inyectable para la administracion por la espina dorsal
MX2021000826A (es) Composicion farmaceutica estable que comprende undecanoato de testosterona.
GEP20196947B (en) Bremelanotide therapy for female sexual dysfunction
BR112013016858A2 (pt) dispositivo para injetar doses ajustáveis de droga líquida
PL414785A1 (pl) Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną
CN302586572S (zh) 无针注射器
MX389818B (es) Composicion de estabilidad mejorada de etanercept.
KR20120119879A (ko) 자가 주사
AR086640A1 (es) Dispositivo y metodo para el llenado de jeringas
EA201401332A1 (ru) Инъекционная композиция на основе витаминов группы b и лидокаина
ES2414663R1 (es) Pieza de conexion para dispositivos inyectables, en particular para jeringas, y jeringas que incluyen dicha pieza

Legal Events

Date Code Title Description
FG Grant or registration